Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

NCT07493161
terminatedphase_2

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053
terminatedphase_2

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832

Clinical Trials (3)

Showing 3 of 3 trials
NCT07493161Not Applicable

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

Not Yet Recruiting
NCT00482053Phase 2

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated
NCT00481832Phase 2

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3